Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;32(1):29-45.
doi: 10.1007/s40273-013-0113-y.

Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies

Affiliations

Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies

Katelijne van de Vooren et al. Pharmacoeconomics. 2014 Jan.

Abstract

Introduction: Diseases caused by Streptococcus pneumoniae (pneumococcus) are a major global public health problem. Despite their importance, information on the burden of the different pneumococcal diseases is limited and estimates vary widely.

Objective and methods: We critically reviewed the full economic evaluations (FEEs) on the new pneumococcal conjugate vaccines (PCVs) conducted in the European Union (EU) to assess their potential contribution to public decision making. We selected the FEEs focussed on PCV-10 and PCV-13 and published in English from January 2007 until June 2013. We screened the selected articles to assess their main methodological features using a common checklist composed of epidemiological, clinical and economic items.

Results: All the ten studies selected were based on modelling and the time horizon was always long term. Two studies focused on adults, the remaining eight on infants. Only one study based herd immunity on national data, eight used foreign data or modelling and the last did not consider it. National prices and tariffs were claimed to be sources for unit costs in all studies; however, half of them assumed price parity when one vaccine was not yet marketed, and the figures varied within the countries where more than one study was conducted. Conclusions supported the economic utility of pneumococcal vaccination in all studies, raising some concern only in (i) the independent study, which found that PCV-13 was borderline cost effective, and (ii) the study sponsored by both manufacturers, which estimated an incremental ratio slightly above the national threshold for both PCV-10 and PCV-13.

Conclusion: The European studies we analysed are mostly based on weak sources of data. Because of the limited information on vaccine effectiveness and lack of epidemiological and economic data, the need for extensive recourse to assumptions leads to great within- and between-study variability generated by authors' choices.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Epidemiol. 1993 May 1;137(9):977-88 - PubMed
    1. An Pediatr (Barc). 2004 Feb;60(2):125-32 - PubMed
    1. Vaccine. 2010 Nov 19;28 Suppl 6:G14-22 - PubMed
    1. Qual Life Res. 2005 Jun;14(5):1311-20 - PubMed
    1. Eur J Clin Microbiol Infect Dis. 2007 Aug;26(8):531-40 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources